|
1
|
Shivarov V and Bullinger L: Expression
profiling of leukemia patients: Key lessons and future directions.
Exp Hematol. 42:651–660. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ross K, Gillespie-Twardy AL, Agha M,
Raptis A, Hou JZ, Farah R, Redner RL, Im A, Duggal S, Ding F, et
al: Intensive chemotherapy in patients aged 70 years or older newly
diagnosed with acute myeloid leukemia. Oncol Res. 22:85–92. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang ES: Treating acute myeloid leukemia
in older adults. Hematology Am Soc Hematol Educ Program.
2014:14–20. 2014.PubMed/NCBI
|
|
4
|
Burnett AK, Russell N, Hills RK,
Panoskaltsis N, Khwaja A, Hemmaway C, Cahalin P, Clark RE and
Milligan D: A randomised comparison of the novel nucleoside
analogue sapacitabine with low-dose cytarabine in older patients
with acute myeloid leukaemia. Leukemia. 29:1312–1319. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mayer J, Arthur C, Delaunay J, Mazur G,
Thomas XG, Wierzbowska A, Ravandi F, Berrak E, Jones M, Li Y and
Kantarjian HM: Multivariate and subgroup analyses of a randomized,
multinational, phase 3 trial of decitabine vs treatment choice of
supportive care or cytarabine in older patients with newly
diagnosed acute myeloid leukemia and poor- or intermediate-risk
cytogenetics. BMC Cancer. 14:692014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kantarjian HM, Thomas XG, Dmoszynska A,
Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R,
Cermak J, et al: Multicenter, randomized, open-label, phase III
trial of decitabine versus patient choice, with physician advice,
of either supportive care or low-dose cytarabine for the treatment
of older patients with newly diagnosed acute myeloid leukemia. J
Clin Oncol. 30:2670–2677. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ramos F, Thépot S, Pleyer L, Maurillo L,
Itzykson R, Bargay J, Stauder R, Venditti A, Seegers V,
Martínez-Robles V, et al: Azacitidine frontline therapy for unfit
acute myeloid leukemia patients: Clinical use and outcome
prediction. Leuk Res. 39:296–306. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lao Z, Yiu R, Wong GC and Ho A: Treatment
of elderly patients with acute myeloid leukemia with azacitidine
results in fewer hospitalization days and infective complications
but similar survival compared with intensive chemotherapy. Asia Pac
J Clin Oncol. 11:54–61. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang J, Lyu H, Wang J and Liu B: MicroRNA
regulation and therapeutic targeting of survivin in cancer. Am J
Cancer Res. 5:20–31. 2014.PubMed/NCBI
|
|
10
|
Larson RA: Micro-RNAs and copy number
changes: New levels of gene regulation in acute myeloid leukemia.
Chem Biol Interact. 184:21–25. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yahya SM and Elsayed GH: A summary for
molecular regulations of miRNAs in breastcancer. Clin Biochem.
48:388–396. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li YQ, Ren XY, He QM, Xu YF, Tang XR, Sun
Y, Zeng MS, Kang TB, Liu N and Ma J: MiR-34c suppresses tumor
growth and metastasis in nasopharyngeal carcinoma by targeting MET.
Cell Death Dis. 6:e16182015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Drebber U, Lay M, Wedemeyer I, Vallböhmer
D, Bollschweiler E, Brabender J, Mönig SP, Hölscher AH, Dienes HP
and Odenthal M: Altered levels of the onco-microRNA 21 and the
tumor-supressor microRNAs 143 and 145 in advanced rectal cancer
indicate successful neoadjuvant chemoradiotherapy. Int J Oncol.
39:409–415. 2011.PubMed/NCBI
|
|
14
|
Weng H, Lal K, Yang FF and Chen J: The
pathological role and prognostic impact of miR-181 in acute myeloid
leukemia. Cancer Genet. 208:225–229. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jinlong S, Lin F, Yonghui L, Li Y, Li Y
and Weidong W: Identification of let-7a-2-3p or/and miR-188-5p as
prognostic biomarkers in cytogenetically normal acute myeloid
leukemia. PLoS One. 10:e01180992015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Z, Huang H, Li Y, Jiang X, Chen P,
Arnovitz S, Radmacher MD, Maharry K, Elkahloun A, Yang X, et al:
Up-regulation of a HOXA-PBX3 homeobox-gene signature following
down-regulation of miR-181 is associated with adverse prognosis in
patients with cytogenetically abnormal AML. Blood. 119:2314–2324.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chu B, Zhong L, Dou S, Wang J, Li J, Wang
M, Shi Q, Mei Y and Wu M: miRNA-181 regulates embryo implantation
in mice through targeting leukemia inhibitory factor. J Mol Cell
Biol. 7:12–22. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang P, Ye B, Yang Y, Shi J and Zhao H:
MicroRNA-181 functions as a tumor suppressor in non-small cell lung
cancer (NSCLC) by targeting Bcl-2. Tumour Biol. 36:3381–3387. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Su R, Lin HS, Zhang XH, Yin XL, Ning HM,
Liu B, Zhai PF, Gong JN, Shen C, Song L, et al: MiR-181 family:
Regulators of myeloid differentiation and acute myeloid leukemia as
well as potential therapeutic targets. Oncogene. 34:3226–3239.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Debernardi S, Skoulakis S, Molloy G,
Chaplin T, Dixon-McIver A and Young BD: MicroRNA miR-181a
correlates with morphological sub-class of acute myeloid leukaemia
and the expression of its target genes in global genome-wide
analysis. Leukemia. 21:912–916. 2007.PubMed/NCBI
|
|
21
|
Cheson BD, Bennett JM, Kopecky KJ, Büchner
T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister
TA, et al: Revised recommendations of the International Working
Group for Diagnosis, standardization of response criteria,
treatment outcomes and reporting standards for therapeutic trials
in acute myeloid leukemia. J Clin Oncol. 21:4642–4649. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cox DR: Regression models and life-tables.
J R Stat Soc Series B Stat Methodol. 34:187–220. 1972.
|
|
24
|
Congdon P: Robust Regression
MethodsApplied Bayesian Modelling. Wiley; Chichester: pp. 118–126.
2003
|
|
25
|
R Core Team, . A language and environment
for statistical computing. Version 3.0.3. 2014. Vienna: R
Foundation for Statistical Computing. http://www.r-project.org/
|
|
26
|
Spiegelhalter D, Thomas A, Best N and Lunn
D: WinBUGS. Version 1.4.3. 2003. Cambridge: Imperial College School
of Medicine & Medical Research Council - Biostatistics Unit.
https://www.mrc-bsu.cam.ac.uk/bugs/winbugs/2003
|
|
27
|
Butrym A, Rybka J, Baczyńska D, Tukiendorf
A, Kuliczkowski K and Mazur G: Expression of microRNA-331 can be
used as a predictor for response to therapy and survival in acute
myeloid leukemia patients. Biomark Med. 9:453–460. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cammarata G, Augugliaro L, Salemi D,
Agueli C, La Rosa M, Dagnino L, Civiletto G, Messana F, Marfia A,
Bica MG, et al: Differential expression of specific microRNA and
their targets in acute myeloid leukemia. Am J Hematol. 85:331–339.
2010.PubMed/NCBI
|
|
29
|
Grenda A, Budzyński M and Filip AA:
Biogenesis of microRNAs and their role in the development and
course of selected hematologic disorders. Postepy Hig Med Dosw
(Online). 67:174–185. 2013.(In Polish). View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Butrym A, Rybka J, Baczyńska D, Tukiendorf
A, Kuliczkowski K and Mazur G: Low expression of microRNA-204
(miR-204) is associated with poor clinical outcome of acute myeloid
leukemia (AML) patients. J Exp Clin Cancer Res. 34:682015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Isken F, Steffen B, Merk S, Dugas M,
Markus B, Tidow N, Zühlsdorf M, Illmer T, Thiede C, Berdel WE, et
al: Identification of acute myeloid leukaemia associated microRNA
expression patterns. Br J Haematol. 140:153–161. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schwind S, Maharry K, Radmacher MD, Mrózek
K, Holland KB, Margeson D, Whitman SP, Hickey C, Becker H, Metzeler
KH, et al: Prognostic significance of expression of a single
microRNA, miR-181a, in cytogenetically normal acute myeloid
leukemia: A cancer and leukemia group B study. J Clin Oncol.
28:5257–5264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Derissen EJ, Beijnen JH and Schellens JH:
Concise drug review: Azacitidine and decitabine. Oncologist.
18:619–624. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dombret H, Seymour JF, Butrym A,
Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC,
Candoni A, et al: International phase 3 study of azacitidine vs
conventional care regimens in older patients with newly diagnosed
AML with >30% blasts. Blood. 126:291–299. 2015. View Article : Google Scholar : PubMed/NCBI
|
